Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.22%
1,070.62
+2.38
+0.22%
—1,068.241,067.921,077.071,063.77——
SIXC
Communications
SIXC
Communications
SIXC
+1.39%
615.04
+8.45
+1.39%
—606.59606.59615.18605.82——
SIXE
Energy
SIXE
Energy
SIXE
-0.21%
1,244.53
-2.68
-0.21%
—1,247.211,244.281,248.081,231.77——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.68%
1,715.89
-11.69
-0.68%
—1,727.581,727.121,727.751,713.72——
SIXM
Financials
SIXM
Financials
SIXM
+0.97%
635.62
+6.08
+0.97%
—629.54628.87637.42628.46——
SIXR
Staples
SIXR
Staples
SIXR
+0.75%
859.99
+6.39
+0.75%
—853.60854.40864.39854.06——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.62%
213.36
+1.32
+0.62%
—212.04212.04214.86212.04——
SIXT
Technology
SIXT
Technology
SIXT
-0.42%
3,534.68
-15.08
-0.42%
—3,549.763,571.063,579.253,510.56——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.38%
883.08
-3.41
-0.38%
—886.49888.59891.95882.30——
SIXV
Health care
SIXV
Health care
SIXV
-0.12%
1,462.54
-1.80
-0.12%
—1,464.341,460.441,471.191,455.16——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+1.00%
2,377.85
+23.60
+1.00%
—2,354.252,352.682,378.072,348.77——
BIOCON:NSE
Biocon Ltd
₹427.00
-0.72%
(-3.10) 1D
May 18, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BIOCON...
Open
₹428.45
High
₹431.85
Low
₹422.35
Mkt. cap
510.63B
Avg. vol.
4.61M
Volume
3.39M
Dividend
0.12%
Quarterly dividend
₹0.13
Ex dividend date
Jul 3, 2026
P/E ratio
151.42
52-wk high
₹434.60
52-wk low
₹327.60
EPS
₹2.82
Shares outstanding
600.00M
No. of employees
16K
News stories
From sources across the web
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. The company was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOSiddharth Mittal
Employees16.4K
FoundedNov 29, 1978
HeadquartersBengaluru, Karnataka, India
SectorBiotechnology
Websitebiocon.com
Last report
May 8, 2026
Fiscal Period
Q4 2026
EPS / Est. (INR)
₹1.27 / ₹1.17
+8.26%beat
Revenue / Est. (INR)
45.17B / 45.26B
-0.20%miss
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
39.42B
42.96B
41.73B
45.17B
Cost of goods sold
14.05B
17.72B
13.39B
13.99B
Cost of revenue
14.05B
17.72B
13.39B
13.99B
Research and development expenses
-346.00M
-132.00M
-531.00M
-128.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.33B
9.59B
8.75B
9.12B
Operating expense
22.43B
21.18B
25.16B
26.10B
Total operating expenses
36.48B
38.90B
38.55B
40.10B
Operating income
2.94B
4.05B
3.18B
5.07B
Other non operating income
-11.62B
94.00M
1.17B
525.00M
EBT including unusual items
969.00M
1.71B
-678.00M
2.48B
EBT excluding unusual items
-11.45B
1.23B
2.26B
3.28B
Income tax expense
77.00M
385.00M
-160.00M
489.00M
Effective tax rate
7.95%
22.48%
23.60%
19.76%
Other operating expenses
9.89B
6.72B
11.78B
11.98B
Net income
314.00M
845.00M
1.44B
1.26B
Net profit margin
0.80%
1.97%
3.45%
2.79%
Earnings per share
0.26
0.72
2.74
1.27
Interest and investment income
-
235.00M
-
-
Interest expense
-2.77B
-2.72B
-2.10B
-2.32B
Net interest expenses
-2.77B
-2.49B
-2.10B
-2.32B
Depreciation and amortization charges
4.55B
4.73B
5.15B
5.13B
EBITDA
6.89B
8.69B
7.13B
9.96B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer